Document is current
Any future updates will be listed below
-
Authors
Samineni, Divya http://orcid.org/0000-0001-6300-2044
Gibiansky, Leonid
Wang, Bei
Vadhavkar, Shweta
Rajwanshi, Richa
Tandon, Maneesh
Sinha, Arijit
Al-Sawaf, Othman
Fischer, Kirsten
Hallek, Michael
Salem, Ahmed Hamed
Li, Chunze
Miles, Dale
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02242942 at ClinicalTrials.govnct02339181 at ClinicalTrials.govDocuments that mention this clinical trial
Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial
https://doi.org/10.1007/s12325-022-02170-w
Bioavailability Evaluation of Venetoclax Lower-Strength Tablets and Oral Powder Formulations to Establish Interchangeability with the 100 mg Tablet
https://doi.org/10.1007/s40261-022-01172-4
Documents that mention this clinical trial
Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial
https://doi.org/10.1007/s12325-022-02170-w
-
Funding
Funding for this research was provided by:
Genetech Inc
- License Information
-
More Information
Article History
Received: 3 February 2022
Accepted: 21 April 2022
First Online: 16 June 2022
